Trypto Therapeutics

Trypto Therapeutics has developed and patented a novel class of TPH inhibitors (TPHi) with nanomolar potency in vitro. Our TPHi differ in their scaffold, binding mode, and potency from TPHi that are currently on the market or under clinical investigation. The lead TPHi compound achieved readiness to transition from academic research towards a targeted pharmaceutical development. At Trypto Therapeutics, we are dedicated to advancing the field of serotonin-related diseases to address pulmonary indications with a high unmet medical need. Our team focuses on developing cutting-edge treatments that harness the power of an inhalative route of administration. We are committed to collaboration and partnership with other organizations in the healthcare sector to propel research and bring our insights to the forefront of the industry. Together, we strive to redefine standards in therapeutic care and improve the lives of patients globally.